Alzheimer’s Treatment Needs More Than Amyloid

TL;DR: A 2026 review in Science China Life Sciences argues that amyloid-beta antibodies such as lecanemab and donanemab are important progress, but Alzheimer’s treatment cannot stop at amyloid. The disease also involves tau tangles, genetics, aging biology, immune changes, vascular and metabolic health, and systemic conditions that shape whether pathology becomes dementia.

Source: Science China Life Sciences (2026) | Jia et al.

Alzheimer’s disease is often introduced through two famous brain lesions: amyloid plaques and tau tangles. That shorthand is useful, but it can accidentally make the disease sound like a two-object cleanup job. Remove the plaques, block the tangles, and cognition should return.

The current treatment reality is more complicated. New amyloid-targeting antibodies can change Alzheimer’s biology and modestly slow clinical decline in selected patients. They have not restored normal memory, reversed established dementia, or turned Alzheimer’s into a solved disease.

This review asks readers to hold both truths at once: amyloid is central, and amyloid is not enough. A durable treatment strategy will likely need to match the right target, disease stage, genotype, and systemic health profile.

Amyloid Antibodies Changed Alzheimer’s Treatment but Did Not Finish It

Amyloid-beta, often written Aβ, is a small protein fragment that can accumulate into plaques in Alzheimer’s disease. These plaques sit outside neurons and are one of the defining pathological features of the disease.

Amyloid-targeting antibodies such as lecanemab and donanemab are designed to help the immune system clear amyloid-related pathology. Their arrival matters because they showed that modifying amyloid biology can slow disease progression in people with early Alzheimer’s disease.

But slowing decline is not the same as restoring cognition. The review uses that gap as the starting point. If removing or reducing amyloid slows the disease but does not reverse cognitive deterioration, then Alzheimer’s symptoms must depend on more than amyloid load alone.

That is not an argument to abandon amyloid. It is an argument to stop expecting amyloid to carry the full treatment burden by itself.

APP Metabolism Explains Why Amyloid Builds Up

The review begins with amyloid precursor protein, or APP. APP is a larger protein that can be cut by enzymes into smaller fragments. Some processing routes produce amyloid-beta, including forms that are more likely to aggregate.

Therapeutically, amyloid can be targeted at several points. A treatment might try to reduce amyloid-beta production, prevent aggregation, increase clearance, or neutralize toxic species. Antibodies mostly sit in the clearance and neutralization part of that landscape.

The difficulty is that amyloid biology is not isolated. Amyloid can interact with tau, inflammation, synaptic function, vascular health, and protein-clearance systems. By the time symptoms are obvious, the disease can have moved beyond a simple amyloid-first stage.

So the timing of amyloid treatment may be crucial. A therapy that helps early can have a smaller effect after widespread tau pathology, synapse loss, and neuronal damage are already established.

Tau Tangles Track the Neuronal Damage More Closely

Tau is a protein that normally helps stabilize the internal skeleton of neurons. In Alzheimer’s disease, tau can become abnormally modified, including through a process called hyperphosphorylation.

Phosphorylation means adding phosphate groups to a protein. Too much or misplaced phosphorylation can change how tau behaves.

Abnormal tau can form neurofibrillary tangles inside neurons. These tangles are more closely linked to neuronal injury and cognitive symptoms than amyloid plaques alone.

This is why tau remains a major therapeutic target. If amyloid helps trigger or accelerate disease but tau tracks the spread of neuronal dysfunction, then a treatment plan focused only on amyloid may leave the symptom-driving machinery active.

The review treats tau as a parallel engine of disease. That framing is important for combination therapy: amyloid treatments often need to be paired with tau-directed approaches, especially as disease advances.

APOE and Other Genes Make Alzheimer’s Risk Uneven

APOE is a gene involved in lipid transport and brain repair processes. The APOE epsilon4 variant is the best-known common genetic risk factor for late-onset Alzheimer’s disease. People who carry APOE epsilon4 have higher risk, although the variant is not a guarantee that a person will develop Alzheimer’s.

Genetics matters for more than risk prediction. It can affect amyloid handling, immune response, vascular biology, and treatment safety. For example, APOE status has been important in discussions of amyloid-related imaging abnormalities, a potential side effect of amyloid antibody treatment involving brain swelling or bleeding signals on MRI.

The review also points beyond APOE to additional population-linked genetic variants. Alzheimer’s risk biology is not evenly distributed across ancestry groups, environments, or health histories, so trial design has to account for that variation.

A future treatment strategy often need to account for genotype, disease stage, amyloid burden, tau burden, vascular risk, immune state, and patient priorities. A single “Alzheimer’s drug” may be less realistic than a staged, biomarker-guided treatment plan.

Aging Biology Changes the Brain’s Tolerance for Pathology

Alzheimer’s is an age-related disease, but age is not just a number on a chart. Aging changes the biological environment in which amyloid and tau act.

With age, several support systems can weaken at once:

• Protein clearance can slow: misfolded proteins become harder to remove.
• Immune tone can shift: brain immune cells can become more inflammatory.
• Energy and blood-flow systems can strain: mitochondria and blood vessels may become less reliable.

Cells may also accumulate stress damage and lose resilience.

These changes can make the same amount of pathology more damaging in one person than another. They also help explain why cognitive resilience varies. Some people tolerate amyloid and tau pathology longer, while others develop symptoms with a smaller apparent burden.

The review’s broader point is that Alzheimer’s treatment should not only attack plaques and tangles. It should also ask how to preserve the tissue environment that allows neurons and synapses to keep working.

Systemic Health Can Push the Brain Toward or Away From Dementia

Systemic factors are body-wide health conditions that influence the brain. In Alzheimer’s disease, this can include vascular disease, diabetes, obesity, sleep disruption, inflammation, infection burden, kidney disease, and other conditions that affect brain resilience.

The brain is metabolically demanding. It depends on blood flow, oxygen delivery, glucose regulation, immune balance, and waste clearance. When those systems are strained, Alzheimer’s pathology may become harder for the brain to tolerate.

Prevention and treatment overlap around these body-wide risk factors. Blood pressure control, metabolic health, exercise, sleep, hearing care, depression treatment, and vascular risk management are not replacements for disease-modifying drugs. But they may affect the biological background in which those drugs work.

The practical implication is that Alzheimer’s care cannot be reduced to a single molecule. A person with amyloid pathology, uncontrolled vascular risk, poor sleep, and high inflammation often need a different treatment package than someone with the same amyloid burden but better systemic health.

The Review Supports Biomarker-Guided Combination Therapy

This paper is a review, not a new clinical trial. It does not test a new drug, enroll patients, or report a new treatment effect. Its value is in organizing the treatment map.

The map points toward biomarker-guided combination therapy. Biomarkers are measurable signs of disease biology, such as amyloid positron emission tomography (positron emission tomography (PET), an imaging method that uses radioactive tracers to map biology in living tissue) scans, tau PET scans, cerebrospinal fluid markers, blood p-tau tests, MRI findings, genetic risk, or inflammatory and metabolic measures.

In a more mature treatment system, those markers can help decide which target comes first, which combinations make sense, and when treatment risk outweighs likely benefit.

Early amyloid-positive patients often need one strategy. Tau-heavy symptomatic patients often need another. Patients with vascular or metabolic risk often need aggressive systemic management alongside brain-directed therapy.

The review’s strongest contribution is the reminder that Alzheimer’s is not a single-pathway disorder. Amyloid antibodies opened an important door, but the next room contains tau, genes, aging, immune biology, metabolism, and vascular health.